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Abstract
Background: Vitamin B12 deficiency causes a number of neurological features including cognitive and psychiatric
disturbances, gait instability, neuropathy, and autonomic dysfunction. Clinical recognition of B12 deficiency in
neurodegenerative disorders is more challenging because it causes defects that overlap with expected disease
progression. We sought to determine whether B12 levels at the time of diagnosis in patients with Parkinson’s disease (PD)
differed from those in patients with other neurodegenerative disorders.
Methods: We performed a cross-sectional analysis of B12 levels obtained around the time of diagnosis in patients with
PD, Multiple System Atrophy (MSA), Dementia with Lewy Bodies (DLB), Alzheimer’s disease (AD), Progressive Supranuclear
Palsy (PSP), Frontotemporal Dementia (FTD), or Mild Cognitive Impairment (MCI). We also evaluated the rate of B12
decline in PD, AD, and MCI.
Results: In multivariable analysis adjusted for age, sex, and B12 supplementation, we found that B12 levels were
significantly lower at time of diagnosis in patients with PD than in patients with PSP, FTD, and DLB. In PD, AD, and MCI,
the rate of B12 decline ranged from − 17 to − 47 pg/ml/year, much greater than that reported for the elderly population.
Conclusions: Further studies are needed to determine whether comorbid B12 deficiency affects progression of these
disorders.
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Background
Vitamin B12 deficiency is common in aging and causes a
number of neurological conditions including cognitive
and psychiatric disturbances, gait instability, neuropathy,
and autonomic dysfunction [1–5]. Because features of
B12 deficiency overlap with those seen in neurodegener-
ative diseases, clinical recognition of this deficiency is
difficult and requires blood measurement.
We recently measured B12 levels at baseline in early, un-
treated Parkinson’s disease (PD) patients from the DATA-
TOP study [6] and found that 5% had deficient level (< 212
pg/ml) and 13% had borderline low level (< 250 pg/ml) [7].
We also found that those participants in the lowest B12 ter-
tile had greater annualized worsening of gait and balance as
assessed by the ambulatory capacity score compared to those
in the middle or upper B12 tertiles [8]. B12 levels, but not
homocysteine, methylmalonic acid, or holotranscobalamin,
were associated with greater gait impairment. Because the
DATATOP study was conducted in the late 1980’s, it is not
known if these rates are accurate in contemporary patients.
Since in our prior study hematological indices (mean cor-
puscular volume and hematocrit) did not help identify pa-
tients with low B12 levels, knowledge of B12 levels among
neurodegenerative conditions could increase the diagnostic
rate of B12 insufficiency in patients with PD and thus allow
for appropriate treatment. In this exploratory study, we
retrospectively analyzed B12 measurements across various
neurodegenerative diseases obtained around the time of
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diagnosis and evaluated the rate of B12 decline in patients
with PD compared to patients with a variety of other neu-
rodegenerative disorders.
Methods
Study design and protocol
The study was approved by Committee on Human Re-
search at University of California, San Francisco (UCSF).
We searched electronic medical records between 2007
and 2015 to identify all patients > 40 years old seen in
the UCSF Department of Neurology with a recorded
B12 measurement, obtained as part of routine clinical
care, at the UCSF Clinical laboratory. During the time-
frame of 2007–15, the UCSF laboratory used the same
Vitamin B12 Chemiluminescent Assay (ADVIA Centaur
System, Siemens). At the low end of the normal range
207 pg/ml, this assay has a 4% within–run coefficient of
variation (CV) and a 4.4% run-to-run CV. In order to
obtain an estimate of endogenous B12 levels and be-
cause levels > 1999 pg/ml are not quantified and only re-
sulted as such, we excluded patients with levels greater
than the UCSF laboratory upper limit of normal (> 911
pg/ml) because these high levels likely reflected excessive
supplementation of B12. As clinical B12 deficiency may
occur at or above the laboratory cutoff (211 pg/ml), we
used a cut-off of < 250 pg/ml to identify patients at
higher risk for developing B12 deficiency [7]. Only pa-
tients with a B12 measurement within ±3 years of neuro-
degenerative disease diagnosis were included in the
analysis. Remaining records were reviewed to confirm
the year of diagnosis and if and when levodopa was
started. Because treatment with metformin and proton
pump inhibitors are associated with reduced B12 levels
while treatment with B12 and/or a multivitamin in-
creases B12 levels, we reviewed the medical record to
determine whether patients had these exposures docu-
mented at the time of the blood draw for B12.
We included the following diagnoses: PD, AD, MSA,
DLB, PSP, FTD and MCI. Patients were categorized accord-
ing to the diagnosis they received at their latest neurology
visit. In order to develop cohorts with as typical a clinical
phenotype as possible, those with a diagnosis of mixed de-
mentia (i.e. vascular dementia plus AD) were excluded. To
evaluate the rate of B12 decline (change in B12 levels/year),
we identified patients diagnosed with PD, AD, or MCI and
who had at least two B12 measurements > 6months apart,
with the first measurement within 3 years of diagnosis. Since
B12 levels in the elderly have been shown to gradually de-
cline over time [9] and in order to estimate the endogenous
rate of decline of B12, we excluded patients with > 10% in-
crease between first and second measurements since such
an increase would likely reflect that the patient had begun
B12 supplementation between measurements.
Statistical analysis
Statistical analyses were performed using Stata version 15.1
(StataCorp, College Station, TX). Patient characteristics
across diagnosis groups were compared using Fisher’s exact
tests for categorical variables and analysis of variance
(ANOVA) for continuous variables. We first examined
covariates potentially associated with B12 levels using uni-
variate linear regression models. Variables significant at the
0.05 level in univariate analysis were then included in a
multivariable model. Although neither age nor sex was sig-
nificantly associated with B12 levels in univariate analysis,
we also included these in the multivariable model. In those
with MCI, AD and PD who had more than one B12 meas-
urement, differences between the two measurements were
calculated and divided by time elapsed to estimate median
rates of decline for each group. These rates were compared
using a non-parametric Kruskal-Wallis test. A significance
threshold of 0.05 was used.
Results
Vitamin B12 levels at baseline
Of those diagnosed with predominant neurocognitive
symptoms (AD, MCI, FTD, DLB), 16% (220/1312) were
excluded due to a B12 level > 911 pg/ml. Of those evalu-
ated for predominant parkinsonism (PD, MSA, PSP),
12% (84/691) were excluded due to having a B12 level >
911 pg/ml. A total of 713 patients met criteria to be in-
cluded in the analysis. Group characteristics across diag-
nostic categories were compared using ANOVA. Age
and sex differed significantly across diagnostic groups
(Table 1). B12 levels at time of diagnosis also varied sig-
nificantly. Although patients with PD were more likely
to have B12 levels< 250 pg/ml, this difference was not
significant. Neither use of a multivitamin nor a sep-
arate B12 supplement was different across groups.
As expected, levodopa use was more common among
those diagnostic groups with parkinsonism (PD,
DLB, MSA, and PSP). The overall percentage of pa-
tients on metformin, a medication associated with a
decline in B12, was low but use was significantly dif-
ferent across groups, with the DLB group having the
greatest metformin use. Use of proton pump inhibi-
tor was not significantly different across groups.
(Table 1).
In univariate analyses examining the potential asso-
ciation of covariates with B12 levels around the time
of disease diagnosis, levels of B12 in MCI, FTD, MCI
and PSP were all found to be significantly higher on
average than levels in those with PD (Table 2). No
differences were observed between B12 levels in pa-
tients with PD and those with either AD or MSA.
Neither age nor sex were associated with B12 levels,
although the 95% CI for age indicated a higher likeli-
hood of decreasing levels with increasing age. Both
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multivitamin use and B12 supplementation were sig-
nificantly associated with increased B12 levels. Neither
use of metformin or a proton pump inhibitor was as-
sociated with significantly lower B12 levels.
In multivariable analysis adjusted for sex, age, multi-
vitamin use and B12 supplementation, patients with
DLB, FTD and PSP all had higher B12 levels on average
than those with PD, although MCI was no longer signifi-
cant (p = 0.068; Table 3). Multivitamin use and B12 sup-
plementation were independently associated with
increased B12 levels.
Rate of vitamin B12 decline
Of those diagnosed with predominant neurocognitive
symptoms (AD, MCI, FTD, DLB), 16% were excluded
due to the first B12 > 911 pg/ml and 23% due > 10% in-
crease in the second B12 measurement compared to
baseline. Of those evaluated for predominant parkinson-
ism, 14% were excluded due to the first B12 > 911 pg/ml
and 27% due to an increase of > 10% at the second
measurement. Since there are fewer patients with two
B12 measurements, we confined the analysis of the
Table 1 Characteristics of cohort
AD (n = 204) DLB (n = 36) FTD (n = 24) MCI (n = 290) MSA (n = 9) PD (n = 130) PSP (n = 20) P-value*
Age at diagnosis, mean
(sd)
74.4 (9.7) 73.4 (8.6) 68.4 (8.6) 70.4 (9.9) 66.1 (3.6) 68 (10.2) 69.9 (6.3) < 0.001**
Age at time of B12,
mean (sd)
73.8 (9.7) 73 (8.6) 67.7 (8.5) 69.8 (9.9) 65.1 (3.8) 68.4 (9.7) 69 (6.1) < 0.001**
Female (%) 118 (57.8) 17 (47.2) 11 (45.8) 150 (51.7) 3 (33.3) 51 (39.2) 9 (45) 0.04
B12 level (pg/ml),
mean (sd)
465.1 (165.5) 518.7 (180.4) 542.9 (159.3) 499.4 (180.7) 549.8 (145.6) 454.7 (168.4) 539.1 (178.1) 0.015**
Patients with B12
< 250 pg/ml (%)
13 (6.4) 2 (5.6) 0 18 (6.2) 0 13 (10.0) 1 (5.0) 0.69
Medications (%)
Levodopa 1 (0.5) 20 (55.6) 0 0 5 (55.6) 116 (89.2) 9 (45) < 0.001
Multivitamin 58 (28.4) 6 (16.7) 6 (25) 85 (29.3) 1 (11.1) 23 (17.7) 3 (15.0) 0.10
Vitamin B12 16 (7.8) 3 (8.3) 2 (8.3) 18 (6.2) 0 2 (1.5) 2 (10.0) 0.13
Metformin 11 (5.4) 7 (19.4) 1 (4.2) 27 (9.3) 0 4 (3.1) 2 (10.0) 0.02
PPII 28 (13.7) 8 (22.2) 4 (16.7) 54 (18.6) 0 16 (12.3) 5 (25.0) 0.27
Abbreviations: MCI mild cognitive impairment; PD Parkinson’s disease; MSA multiple systems atrophy; DLB dementia with Lewy bodies; AD Alzheimer’s disease; PSP
progressive supranuclear palsy; FTD frontotemporal dementia; PPI proton pump inhibitor
*calculated using Fisher’s exact test unless otherwise indicated
**calculated using analysis of variance
Table 2 Univariate linear regression of factors associated with
B12 levels at time of diagnosis
Diagnosis Coefficient (95% CI) P-value
Parkinson’s disease Ref
Alzheimer’s disease 10.4 (−27.7, 48.5) 0.59
Dementia with Lewy bodies 63.9 (−0.06, 128) 0.05
Frontotemporal dementia 88.2 (12.7, 164) 0.02
Mild cognitive impairment 44.6 (9.77, 80.5) 0.015
Multiple systems atrophy 95.0 (−22.1, 212) 0.11
Progressive supranuclear palsy 84.4 (2.74, 166) 0.04
Female gender −9.56 (−35.2, 16.1) 0.47
Age at diagnosis −0.99 (−2.28, 0.29) 0.13
Multivitamin use 91.1 (62.4, 120) < 0001
B12 supplementation 88.7 (35.3, 142) 0.001
Metformin 23.0 (−26.3, 72.3) 0.36
Proton Pump Inhibitor 0.62 (−34.2, 35.5) 0.97
Table 3 Multivariable analysis of factors associated with B12
level at time of diagnosis
Diagnosis Coefficient* (95% CI) P-value
Parkinson’s disease (PD) Ref
Alzheimer’s disease (AD) 1.90 (−36.4, 40.2) 0.92
Dementia with Lewy bodies (DLB) 64.3 (1.94, 127) 0.04
Frontotemporal dementia (FTD) 76.4 (3.24, 149) 0.04
Mild cognitive impairment (MCI) 32.8 (−2.39, 68.0) 0.068
Multiple systems atrophy (MSA) 100.4 (−12.8, 214) 82
Progressive supranuclear palsy (PSP) 81.6 (2.55, 161) 0.04
Female gender −7.65 (−32.6, 17.3) 0.55
Age at diagnosis −0.86 (−2.14, 0.41) 0.185
Multivitamin use 93.5 (65.0, 122) < 0.001
B12 supplementation 86.4 (34.3, 139) 0.001
*In a linear regression, coefficients are interpreted as follows: a one unit
increase in x results in an increase in B12 pg/ml of (coefficient) pgs. For
example, the coefficient associated with DLB is interpreted: Compared to
patients with PD, patients with DLB have on average a B12 level that is 64.3
pg/ml higher at the time of diagnosis
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change in B12 level/year across the PD, MCI and AD
groups, and a total of 69 patients were included in the
analysis (Fig. 1). Median (interquartile range) rate of de-
cline for those with PD, MCI, and AD were − 17 (− 35,
− 0.4), − 47 (− 112, − 8), and − 29 (− 124, 2.4) pg/ml/year,
respectively. Rate of decline did not differ significantly
across groups.
Discussion
In this cohort of patients with neurodegenerative condi-
tions, we found that B12 levels obtained within 3 years of
neurological diagnosis were significantly lower in patients
with PD than in patients with PSP, FTD, and DLB when
adjusted for sex, age, and B12-supplementing medications.
The rate of B12 decline in PD, MCI, and AD ranged from
17 to 47 pg/ml/year, far in excess of the approximately 5
pg/ml/year measured in a study of normal elderly adults
[9]. These findings are of clinical importance since we have
previously found an association of low B12 levels with
more rapid development of gait impairment in PD [7] but
is also relevant in patients with other neurodegenerative
diseases, who are expected to develop cognitive impairment
and/or gait instability due to disease progression. Failure to
identify and treat this deficiency at diagnosis or in the years
after diagnosis may well increase patient morbidity.
As expected, B12 supplementation and multivitamin use
were associated with higher B12 levels. Multivitamin use
ranged from 11 to 29% while separate B12 supplement
use ranged from 1.5–10%. These rates were similar to the
rates of use of about 41 and 5%, respectively, in a recent
study of a large PD cohort [10] and were not statistically
different across groups. Both the age of diagnosis and per-
centage of females were lower in PD and MSA, but linear
regression models showed that age and sex were not asso-
ciated with B12 levels.
One of the limitations of this study is that we did not
have information on patient body mass index (BMI) and
nutrition risk index. Obesity and elevated BMI have been
shown to be associated with lower vitamin B12 levels [11],
whereas in hospitalized patients at nutritional risk, high
B12 levels (> 1000 pg/nl) have been shown to be associ-
ated with increased mortality [12]. In contrast, our study
targeted outpatients with early neurodegenerative disease
excluded patients with levels over 911 pg/ml, and is there-
fore was different patient population. However, since pa-
tients with advanced neurodegenerative diseases are at
higher risk for impaired nutritional status, future studies
of moderately advanced neurodegenerative disease should
evaluate associations of B12 with mortality.
A systematic literature review testing for an association
of low vitamin B12 levels with development of cognitive
impairment has been inconclusive [13], although studies
using more specific biomarkers of low B12 status (methyl-
malonic acid and holotranscobalamin) have shown signifi-
cant associations [14]. While in our study, the B12 levels
were lower and comparable in PD and AD patients, Bos-
ton et al. (2019) have shown that vitamin B12 levels were
not significantly lower in AD patients compared to healthy
controls [15]. One reason for the apparent difference in
our findings may be that we only looked at patients within
3 years of AD diagnosis. Our study also lacks a healthy
control group for comparison.
In PD particularly, lower B12 levels might be more
likely to develop for a number of reasons, including
change in dietary intake of B12 (some adopt a low-
protein diet), Helicobacter pylori infection, delayed gas-
tric emptying and development of constipation, which is
Fig. 1 Rate of B12 Decline in PD, MCI, and AD patients. Plots showing individual declines of B12 in patients with PD, MCI, and AD. Median
(interquartile range) rate of decline were − 17 (−35, − 0.4), −47 (−112, −8), and − 29 (− 124, 2.4) pg/ml/year for PD, MCI, and AD, respectively
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associated with bacterial overgrowth [16]. Finally, the
prevalence of borderline low B12 (< 250 pg/ml) in 10%
of PD patients in this cohort from 2007 to 2015 was
similar to what was observed in the DATATOP study
(13%) [6], suggesting that it remains a fairly common co-
morbidity in PD.
Our prior study showing that low B12 levels predicted
greater progression of gait instability did not demonstrate
similar predictive characteristics associated with other B12
analytes traditionally used to establish a diagnosis of B12
deficiency, including methylmalonic acid, homocysteine
and holotranscobalamin [7]. This observation raises the
question as to whether B12 levels might have a more dir-
ect effect on PD progression. Interestingly, Schaffner and
colleagues recently reported that B12 directly modulates
leucine–rich repeat kinase 2 (LRRK2) [17]. Mutations in
LRRK2 account for about 5% of hereditary PD [18] and
the most common variant (G2019S) has been established
to increase LRRK2 activity [19, 20]. Since Schaffner and
colleagues found that higher levels of B12 inhibit LRRK2
kinase activity, their work suggests that low B12 levels
may directly contribute to PD pathogenesis by allowing
for increased LRRK2 activity [21].
While aggregation of specific proteins (α-synuclein and
β-amyloid) are defining characteristics PD and AD path-
ology, the role of these proteins in the early pathogenesis
of the sporadic forms of these disorders is not clear and
has led some to hypothesize that insight into disease
modifying targets requires discovery of other biomarkers
present at disease onset and subsequent subgroup analysis
according to these candidate biomarkers [22, 23]. Data
from this study, showing that B12 levels are lower in PD
than other neurodegenerative diseases, along with recent
clinical [7] and biochemical data [17] suggest that B12
warrants further study as an early PD biomarker.
Of note in hospitalized patients, high vitamin B12
levels have been associated with increased in-hospital
mortality [12, 24–26]. This may be because cobalamin is
an acute phase reactant, and elevated cobalamin levels
have been reported in patients with oncologic diseases,
hepatic disease, and in the elderly, hospitalized and crit-
ically ill medical patients who were not taking B12 sup-
plements [12, 27]. Since it is unknown whether there is
a relationship between high vitamin B12 levels and mor-
tality in patients with neurodegenerative disorders, fu-
ture studies should explore this question.
To our knowledge, this is the largest study to assess B12
levels across early neurodegenerative diseases. However,
our study is limited by its observational design and small
sample size for the less common disorders. Because the
study was retrospective and was based in the Movement
Disorder and the Behavioral Neurology clinics at UCSF, a
suitable control group with B12 measurements was not
available. Although B12 measurements are commonly
obtained in the initial evaluation of patients with gait or
cognitive conditions, in this study B12 measurements were
drawn as part of usual clinical practice. It is therefore pos-
sible that initial or repeat B12 levels were more likely to
be measured in those who developed neuropathy, possibly
causing ascertainment bias and/or an overestimate of an-
nualized decline in B12 levels. Also, since supplement use
was based on retrospective chart review, this information
is likely to be less accurate than that collected as part of a
prospective study. Finally, although we were not able to
correlate disease stage with B12 levels, because the ana-
lysis was restricted to patients with B12 levels measured
within 3 years of diagnosis, these patients were predomin-
antly in early disease stages.
Conclusion
Our finding of a lower B12 level around the time of diag-
nosis in PD compared to PSP, FTD, and DLB and greater
rates of B12 decline in those with PD, AD and MCI sup-
ports the need for increased vigilance for B12 deficiency in
these conditions. Future studies are needed to confirm
these findings and determine whether low B12 is associ-
ated with more rapid disease progression and if so,
whether early B12 supplementation reduces morbidity.
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